Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.

"Declarations GuarantorThe scientific guarantor of this publication is Gao-Jun Teng. Conflict of interestThe authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. Statistics and biometryNo complex statistical methods were necessary for this paper. Informed consentWritten informed consent was waived by the Institutional Review Board. Ethical approvalThe study was approved by the institutional review board (IRB) approval as well as applicable local laws and regulatory requirements (Ethics Approval ID: 2021ZDSYLL179-P01). Study subjects or cohorts overlapNone. Methodology• retrospective• observational• multicenter study Conflict of interest The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article."

"Funding The study was supported by the National Key Research and Development Program (2018YFA0704100, 2018YFA0704104), National Natural Science Foundation of China (81827805, 81901847), Jiangsu Provincial Special Program of Medical Science (BE2019750), Postgraduate Research&Practice Innovation Program of Jiangsu Province (KYCX21_0158), and Interventional Medicine Research Special Program of Jiangsu Medical Association (SYH-3201140-0031(2021026))."

"The multicenter, retrospective, cohort study included patients with intermediate or advanced HCC treated with TACE plus camrelizumab and apatinib (combination group) or TACE alone (monotherapy group) between January 2018 and May 2021 from a nationwide registry in China. This study was approved by the institutional review board of Clinical Research of Zhongda Hospital, affiliated with Southeast University (Ethics Approval ID: 2021ZDSYLL179-P01), and written informed consent was waived. The study was conducted per the Declaration of Helsinki and registered at www.clinicaltrials.gov (NCT04975932). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for the observational cohort was followed. The study included patients from the subset of the CHANCE001 study [] and subsequent expansion cohorts, and all data were derived from the database of the national registry platform entitled “Chinese Liver Cancer Clinical Study Alliance (CHANCE)” sponsored by the Chinese College of Interventionalists (CCI). All patients included in this study were not enrolled in those industry-sponsored clinical trials."